Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Intermediate and High Risk Smoldering Multiple Myeloma
NCT02603887Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2016
- Primary completion
- Dec 2017
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in smoldering multiple myeloma (SMM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 168 days. Started Jul 2016; status: active, not recruiting.
02
Drugs
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT02603887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02603887.